The Cancer Letter

Inside information on cancer research and drug development

Funding Opportunities

EGFR Resisters/LUNGevity issues RFA for FY21 award program in EGFR-positive lung cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

EGFR Resisters and LUNGevity Foundation have issued a Request for Application for the EGFR-Positive lung cancer research program.

Funded research is expected to include at least one aim that is translational and must be directly related to improvement in patient outcomes and/or lead to a clinical trial. The EGFR-Positive award is open to researchers at U.S. and international institutions. At the time of application, an international candidate must name a co-principal investigator who is employed at a U.S. institution. A successful applicant may receive up to $200,000 over an award term of two years.

The Request for Applications will be posted as of June 18 on the LUNGevity website and on the proposalCENTRAL website. For more information, contact Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.

Table of Contents

YOU MAY BE INTERESTED IN

Obituary

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
By Melinda Krigel
Obituary

Feng’s team advanced the understanding of biomarkers in prostate cancer

The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.
By NRG Staff
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account